Clinical analysis of thymosin combined with liver protecting drugs in the treatment of primary hepatocellular carcinoma

VernacularTitle:胸腺肽联合保肝类药物治疗原发性肝癌的临床分析
Author: Yuan BU
Keywords: Liver neop; asms; Thymosin; Hepatoprotective drugs
From: Chinese Journal of Primary Medicine and Pharmacy 2017;24(13):2059-2061
CountryChina
Language:Chinese
Abstract: Objective To investigate the clinical effect of thymosin combined with liver gland peptide drugs in the treatment of primary liver cancer.Methods 138 cases of primary hepatocellular carcinoma (HCC) were seleted as the research subjects,and they were divided into observation group (n=69) and control group (n=69) according to the number table method.The control group was treated with simple hepatoprotective drugs,the observation group was treated with thymosin on the basis of the control group.The clinical curative effect of the two groups,quality of life improvements were observed.Results In the observation group,the total effective rate was 81.16%,which in the control group was 43.47%,the difference was statistically significant between the two groups (χ2=8.362,P<0.05).The rate of life quality improvement of the observation group was 60.86%,which of the control group was 23.18%,there was statistically significant difference between the two groups (χ2=9.726,P<0.05).Conclusion The primary HCC patients treaed with thymosin combined with hepatoprotective drugs can effectively improve the patients' life quality,with good clinical curative effect,and it is worth clinical promotion and application.